Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

NCT07269470 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Chronic Myeloid Leukemia

Interventions

DRUG: Dasatinib
DRUG: Ropeginterferon alfa-2b (P1101)

Sponsor

M.D. Anderson Cancer Center